Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer
Status:
Recruiting
Trial end date:
2023-06-21
Target enrollment:
Participant gender:
Summary
This phase I/II studies the side effects and best dose of regorafenib when given together
with pembrolizumab in treating participants with colorectal cancer that has spread to other
places in the body. Drugs used in chemotherapy, such as regorafenib, work in different ways
to stop the growth of tumor cells, either by killing the cells, by stopping them from
dividing, or by stopping them from spreading. Monoclonal antibodies, such as pembrolizumab,
may interfere with the ability of tumor cells to grow and spread. Giving regorafenib and
pembrolizumab may work better at treating colorectal cancer.